Article PDF
References
Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000;57: 418–420.
Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41: 638–645.
Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. J Am Med Assoc 2003;290: 2443–2454.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. New Engl J Med 2002;346: 257–270.
Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62: 509–525.
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358: 1668–1675.
Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44: 414–425.
Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (2nd edit). Cephalalgia 2004;24: 1–160.
Olesen J, Tfelt-Hansen P, Ramadan N, Goadsby PJ, Welch KMA. The Headaches. Philadelphia: Lippincott, Williams & Wilkins, 2005.
Bertin L, Brion N, Farkkila M, Gobel H, Wessely P. A dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Int J Clin Pract 1999;53: 593–598.
Dahlof C. Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine: a review of data from clinical trials. Cephalalgia 2001;21(suppl 1): 9–12.
Pierce M, Marbury T, O’Neill C, et al. Zelrix: a novel transdermal formulation of sumatriptan. Headache 2009;49: 817–825.
Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009;49: 1435–1444.
Silberstein SD, Kori SH, Tepper SJ, et al. Efficacy and tolerability of MAP0004, a novel orally inhaled therapy, in treating acute migraine. Cephalalgia 2009;29: 12.
Goadsby PJ. Emerging therapies for migraine. Nature Clin Pract Neurol 2007;3: 610–619.
Humphrey PPA, Feniuk W, Perren MJ, et al. Serotonin and migraine. Ann NY Acad Sci 1990;600: 587–598.
Leysen JE, Gommeren W, Heylen L, et al. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1Da, human 5-hydroxytryptamine1Db, and calf 5-hydroxytryptamine1D receptors investigated with [3H]-5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 1996;50: 1567–1580.
Diener HC, Tfelt-Hansen P, e Beukelaar F, et al. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Cephalalgia 2001;21: 672–679.
Goadsby PJ, Classey JD. Evidence for 5-HT1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 2003;122: 491–498.
Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001;358: 1230–1234.
Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthesis inhibition in migraine. Lancet 1997;349: 401–402.
Ashina M, Lassen LH, Bendtsen L, Jensen R, Olesen J. Effect of inhibition of nitric oxide synthase on chronic tension-type headache. Lancet 1999;353: 287–289.
Iversen H. Human migraine models. Cephalalgia 2001;21: 781–785.
Hoye K, Laurijssens BE, Harnisch LO, et al. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine. Cephalalgia 2009;29: 132.
Palmer JE, Guillard FL, Laurijssens BE, et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 2009;29: 124.
Medve RA, Andrews JS. Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura. Cephalalgia 2009;29: 126.
Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28: 183–187.
Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33: 48–56.
Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Brit J Pharmacol 2000;129: 420–423.
Salvatore CA, Mallee JJ, Bell IM, et al. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 2006;45: 1881–1887.
Williams TM, Stump CA, Nguyen DN, et al. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg Med Chem Lett 2006;16: 2595–2598.
Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350: 1104–1110.
Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372: 2115–2123.
Zagami AS, Edvinsson L, Hoskin KL, Goadsby PJ. Stimulation of the superior sagittal sinus causes extracranial release of PACAP. Cephalalgia 1995;15(suppl 14): 109.
Henrik S, Steffen B, Wienecke T, et al. PACAP38 induces migraine-like attacks and vasodilatation: a causative role in migraine pathogenesis? Brain 2009;132: 16–25.
Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilatation but does not induce migraine. Cephalalgia 2007;28: 226–236.
Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 2006;26: 1168–1170.
Goadsby PJ, Hargreaves R. Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache 2008;48: 799–804.
Schulman EA, Lake AE, 3rd, Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society. Headache 2008;48: 778–782.
Schulman EA, Lake AE, 3rd, Goadsby PJ, et al. Defining refractory migraine: results of the RHSIS survey of American Headache Society members. Headache 2009;49: 509–518.
Saper J, Goadsby PJ, Silberstein S, Dodick DW. Occipital nerve stimulation (ONS) for treatment of intractable chronic migraine (ICM): 3-month results from the ONSTIM feasibility study. Neurology 2009;72: A252.
Lipton RB, Goadsby PJ, Cady RK, et al. PRISM study: occiptal nerve stimulation for treatment-refractory migraine. Cephalalgia 2009;29: 30.
Matharu MS, Bartsch T, Ward N, et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2004;127: 220–230.
Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of durai afferent input. Brain 2002;125: 1496–1509.
Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurones to cervical input after stimulation of the dura mater. Brain 2003;126: 1801–1813.
Bums B, Watkins L, Goadsby PJ. Successful treatment of medically intractable cluster headache using occipital nerve stimulation (ONS). Lancet 2007;369: 1099–1106.
Burns B, Watkins L, Goadsby PJ. Treatment of hemicrania continua by occipital nerve stimulation using the novel bion device: long term follow up of six patients. Lancet Neurol 2008;7: 1001–1012.
May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. Hypothalamic activation in cluster headache attacks. Lancet 1998;352: 275–278.
May A, Ashburner J, Buchel C, et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nature Med 1999;5: 836–838.
Leone M, Franzini A, Bussone G. Stereotatic stimulation of the posterior hypothalamic gray matter in a patient with intractable cluster headache. New Engl J Med 2001;345: 1428–1429.
Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 2010;9: 373–380.
Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994;117: 199–210.
Holland PR, Schembri CT, Fredrick JP, Goadsby PJ. Transcranial magentic stimulation for the treatment of migraine aura. Neurology 2009;72: A250.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goadsby, P.J. Headache. Neurotherapeutics 7, 149–152 (2010). https://doi.org/10.1016/j.nurt.2010.03.007
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2010.03.007